Kenya Prepares Remdesivir Treatment for Bundibugyo Ebola Outbreak
Kenya is preparing to administer the COVID-19 antiviral pill Remdesivir to treat patients infected with the rare Bundibugyo strain of the Ebola virus under a compassionate-use programme, businessdailyafrica.com reported. The move comes as health officials investigate whether the drug manufactured by Gilead Sciences can aid recovery from a strain that currently lacks any approved vaccines or specific treatments.
Monoclonal Antibodies and Treatment Protocols in Nairobi
By October 19, eight cases had been confirmed, and seven patients were already being given monoclonal antibodies obtained from Rwanda, as reported by Director-General for Health Patrick Amoth. These laboratory-made proteins bind to specific viral targets to help the immune system fight the infection. Health authorities plan to start the second part of the compassionate treatment using Remdesivir, an antiviral medicine that interferes with the replication process of viruses inside the body.
The current outbreak began when a man travelled from the Democratic Republic of the Congo through Uganda to Nairobi, where he died on October 5. The Ministry of Health confirmed a total of eight infections by October 19, including a hospital attendant who was exposed to the initial patient.
Evaluating Remdesivir Across Regional and Global Trials
While Remdesivir was used extensively during the COVID-19 pandemic—showing a median recovery time of 10 days compared to 15 days for a placebo in a 2020 clinical trial—its specific effectiveness against Bundibugyo Ebola remains unproven. Kenya is collaborating with the World Health Organization, Uganda, and the Democratic Republic of the Congo to evaluate the drug’s potential in relieving symptoms and improving patient outcomes.
Uganda also utilized Remdesivir under a compassionate-use protocol during the 2026 Bundibugyo Ebola outbreak. The medication was administered to every single one of the 18 patients who checked into Uganda’s Ebola treatment unit, based on findings from a US Centers for Disease Control and Prevention report, although this usage did not provide conclusive evidence that the drug was responsible for their recuperation. Beyond compassionate use, the WHO-supported PARTNERS trial in the DRC is studying Remdesivir alone or combined with the experimental monoclonal antibody MBP134 to assess survival rates.
Pharmaceutical Industry Discussions on Repurposing Antivirals
In a related pharmaceutical development, a senior executive at Merck & Co. discussed whether the company’s own COVID antiviral drug could be deployed as part of the response to ongoing Ebola outbreaks, intent.health reported. Drug manufacturers and public health agencies increasingly examine existing medicines for repurposing during health emergencies to bypass the multi-year timeline required to develop brand-new treatments from scratch.
Worth a look